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infections and disseminated disease involving
multiple organs in immunocompromised
patients. In such cases the disease can mimic
septicemic melioidosis (4,5).
In this previously healthy patient, infection
probably originated from the facial abscess. The
patient was negative for HIV antibody
(Serodia), had no history of diabetes mellitus or
other compromising illnesses, and had no
evidence of immunodeficiency. In a previous
case of disseminated C. violaceum infection in a
young patient, postmortem findings revealed
numerous cortical infarcts and hemorrhages (6).
Our isolate from a brain abscess is yet another
case of a relatively avirulent saprophytic
microorganism resulting in a deep-seated
infection in a well-nourished, previously
healthy person.
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First Glycopeptide-Resistant
Enterococcus faecium Isolate from
Blood Culture in Ankara, Turkey
To the Editor: Glycopeptide-resistant entero-
cocci infections are a major problem in hospi-
tals. Infection or colonization by vancomycin-
resistant enterococci was first reported in
France (1) and the United Kingdom (2); since
then, these organisms have been reported
throughout the world. In Turkey, vancomycin
and teicoplanin have been used to treat serious
methicillin-resistant Staphylococcus aureus and
ampicillin-resistant enterococci infections.
We describe the case of an acute myelocytic
leukemia patient with vancomycin-resistant
enterococci bloodstream infection. This is the
first glycopeptide-resistant Enterococcus
faecium isolate from our hospital and from
Ankara, Turkey. The patient had not been
cared for at another institution.
A 68-year-old man, hospitalized with acute
myelocytic leukemia, had fever episodes during
the neutropenia following three courses of
remission-induction chemotherapy
(daunorubicin+cytosine arabinoside). A combi-
nation of antibiotics including vancomycin,
ceftazidime (sometimes imipenem), and
amikacin was administered with different
regimens during the 5 months of hospitaliza-
tion. Blood, urine, and rectal swab cultures
during this period were positive for different
Enterobacteriaceae spp. but always negative for
vancomycin-resistant enterococci. For long-term
hospitalizations, our center routinely performs
surveillance rectal swab cultures. At the end of
month 5, E. faecium was isolated from the blood
cultures, just 1 day before the patient’s death.
The strain was identified by conventional
methods, commercial automatic systems (API
Strep-Biomerièux, France), and polymerase
chain reaction. Susceptibility patterns showed
that the isolate was resistant to all antibiotics
except ciprofloxacin and levofloxacin. When the
E-test was used, MIC levels for vancomycin,
teicoplanin, ciprofloxacin, and levofloxacin were
256 µg/mL, 64 µg/mL, 0.75 µg/mL, and 1.5 µg/
mL, respectively. VAN-A1 and Van-A2 type
resistance genes were detected by polymerase
chain reaction. Hacettepe University microbiol-
ogy laboratories confirmed these results (3,4).
After this strain was isolated, 1,266 stool
and 176 rectal swab samples were taken from
hospital personnel in three sessions >1 week
apart, and patients were tested for vancomycin-
resistant enterococci. Swab cultures from all
environmental surfaces (bed rails, bedside
commodes, carts, charts, doorknobs, faucet
handles) were also examined. We injected all
samples with 5% sheep blood agar with vanco-
mycin (6 mg/L); vancomycin-resistant E. faecium
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This was the first case of high-level vanco-
mycin-resistant enterococci with a class A
phenotype isolated from a person in our hospi-
tal or in Ankara, Turkey. To prevent the
organism’s spread, we implemented the recom-
mendations of the Hospital Infection Control
Practices Advisory Committee (5).
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Antimicrobial-Drug Use
and Methicillin-Resistant
Staphylococcus aureus
To the Editor: We read with great interest the
debate on the contribution of antimicrobial
selection pressure to changes in resistance in
Salmonella enterica serovar Typhimurium and
the comparison made with methicillin-resistant
Staphylococcus aureus (MRSA) (1).
We strongly agree with Davis et al. that
infection control practices must play a central
role in successful MRSA control programs.
However, we disagree that the antimicrobial-
drug use practices that contribute to the control
of MRSA have not been scientifically defined. In
a recent review, we identified more than 20
studies on consistent associations, dose-effect
relationships, and concomitant variations, all
supporting a causal relationship between
antimicrobial-drug use and MRSA (2).
Since our review, seven other studies
have reported on the contribution of
antimicrobial-drug use to MRSA colonization
and infection in patients, or to high MRSA rates
in health-care settings (3-9). One study reports
a decrease in the rate of new MRSA cases after
major reduction in antimicrobial-drug use (5).
Although a lower number of discharges and a
shorter hospital stay recorded during the 2-year
postintervention period have been proposed as
other explanations (10), the sharp decrease in
new MRSA cases after the new antibiotic
formulary was implemented (a delay of only a
few months) supports the hypothesis that
reduced antimicrobial pressure contributed to the
decline. Additionally, at the recent 4th Decen-
nial International Conference on Nosocomial
and Healthcare-Associated Infections, at least
five reports addressed either (a) antimicrobial-
drug use and increased MRSA incidence or (b)
antimicrobial-drug use as an independent risk
factor for MRSA acquisition or for persistent
MRSA colonization after mupirocin
treatment (11).
When antimicrobial classes are taken into
account separately, cephalosporins and
fluoroquinolones are often identified as risk
factors for MRSA (2-5,8,11). The mechanisms
that would explain the participation of these
two classes are not fully understood. However,
fluoroquinolones directly enhance the expres-
sion of high-level oxacillin-resistant S. aureus
in vitro (11, p.202). Another recent study shows
that sub-MIC levels of ciprofloxacin increase
adhesion of quinolone-resistant MRSA (12),
which could explain persistent MRSA coloniza-
tion and failure of mupirocin treatment in
patients who received a fluoroquinolone (11,
p.197). MRSA outbreaks in surgical patients
have been controlled by isolating patients and
abandoning third-generation cephalosporins for
surgical prophylaxis (3). As stated by Davis et
al., dissemination of epidemic clones does not
necessarily require antimicrobial selection
pressure; however, the above studies suggest
participation of antimicrobial drugs in MRSA
colonization and outbreaks.
Finally, when citing Dutch infection control
measures as an example of successful control of
MRSA, Davis et al. omit the fact that, among
European countries, the Netherlands has the
lowest antimicrobial-drug use in primary health